SCHEMBL6344409

SCHEMBL6344409

CC(C)(CCCSCCCSCCCC(C)(C)C(=O)OCc1ccccc1)CC(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SLC15A1 P46059 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CDC25B P30305 1/20 0.36
PRKCA P17252 1/20 0.35
PRKCD Q05655 1/20 0.35
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ABCC3 O15438 1/20 0.35
NR1I2 O75469 1/20 0.35
ABCB11 O95342 1/20 0.35
NR3C1 P04150 1/20 0.35
RARG P13631 1/20 0.35
CNR1 P21554 1/20 0.35
OPRK1 P41145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352946 0.93 ALDH1A1 (0.40) ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2
SCHEMBL6701639 0.93 ALDH1A1 (0.46) ALDH1A1MAPK1L3MBTL1SMN1; SMN2CDC25B
SCHEMBL6345166 0.85 ALDH1A1 (0.46) ALDH1A1MAPK1L3MBTL1SMN1; SMN2PRKCA
SCHEMBL3286514 0.85 ALDH1A1 (0.41) ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2
SCHEMBL6180729 0.84 ALDH1A1 (0.40) ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2
SCHEMBL6350515 0.82 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1SMN1; SMN2CDC25B
SCHEMBL6695691 0.82 ALDH1A1 (0.39) ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2
SCHEMBL8742579 0.80 ALDH1A1 (0.41) ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2
SCHEMBL6344402 0.80 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL6354484 0.79 ELANE (0.39) ALDH1A1L3MBTL1PPARARAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020077316-A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses ESPERION THERAPEUTICS, INC. 2002-06-20 US claimed
WO-2005068418-A1 SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2005-07-28 WO disclosed
US-20050020694-A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses ESPERION THERAPEUTICS, INC. 2005-01-27 US disclosed
EP-1363879-A2 SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES Esperion Therapeutics Inc. (US) 2003-11-26 EP disclosed
WO-2002030884-A2 SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077316-A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses GSS, IAPP, STS ALDH1A1 2827/4885MAPK1 1289/4885L3MBTL1 3636/4885
US-20050020694-A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses GSS, STS, CBS ALDH1A1 2643/4885MAPK1 1252/4885L3MBTL1 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.